These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 30885334)

  • 1. A study of ALK-positive pulmonary squamous-cell carcinoma: From diagnostic methodologies to clinical efficacy.
    Wang H; Sun L; Sang Y; Yang X; Tian G; Wang Z; Fang J; Sun W; Zhou L; Jia L; Tsao MS; Shi H; Lin D
    Lung Cancer; 2019 Apr; 130():135-142. PubMed ID: 30885334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of ALK detection by FISH, IHC and NGS to predict benefit from crizotinib in advanced non-small-cell lung cancer.
    Lin C; Shi X; Yang S; Zhao J; He Q; Jin Y; Yu X
    Lung Cancer; 2019 May; 131():62-68. PubMed ID: 31027700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Responses to crizotinib in patients with ALK-positive lung adenocarcinoma who tested immunohistochemistry (IHC)-positive and fluorescence in situ hybridization (FISH)-negative.
    Ma D; Wang Z; Yang L; Mu X; Wang Y; Zhao X; Li J; Lin D
    Oncotarget; 2016 Sep; 7(39):64410-64420. PubMed ID: 27418132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ALK FISH patterns and the detection of ALK fusions by next generation sequencing in lung adenocarcinoma.
    Dacic S; Villaruz LC; Abberbock S; Mahaffey A; Incharoen P; Nikiforova MN
    Oncotarget; 2016 Dec; 7(50):82943-82952. PubMed ID: 27769042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combinational Analysis of FISH and Immunohistochemistry Reveals Rare Genomic Events in ALK Fusion Patterns in NSCLC that Responds to Crizotinib Treatment.
    Li W; Zhang J; Guo L; Chuai S; Shan L; Ying J
    J Thorac Oncol; 2017 Jan; 12(1):94-101. PubMed ID: 27614248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A standardized protocol for detection of ALK protein expression and gene fusion in lung adenocarcinoma cytologic specimens].
    Wang Z; Wu X; Shi Y; Han X; Cheng G; Li L; Mu X; Zhang Y; Cui D; Zhang L; Fan Z; Zhu G; Ma L; Yang L; Di J; Liu D
    Zhonghua Zhong Liu Za Zhi; 2015 Oct; 37(10):742-8. PubMed ID: 26813592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Attenuated isolated 3' signal: A highly challenging therapy relevant ALK FISH pattern in NSCLC.
    Smuk G; Pajor G; Szuhai K; Morreau H; Kocsmár I; Kocsmár É; Pajor L; Kajtár B; Sárosi V; Lotz G; Tornóczky T
    Lung Cancer; 2020 May; 143():80-85. PubMed ID: 32272316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RNA-based analysis of ALK fusions in non-small cell lung cancer cases showing IHC/FISH discordance.
    Vollbrecht C; Lenze D; Hummel M; Lehmann A; Moebs M; Frost N; Jurmeister P; Schweizer L; Kellner U; Dietel M; von Laffert M
    BMC Cancer; 2018 Nov; 18(1):1158. PubMed ID: 30466405
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ALK immunohistochemistry positive, FISH negative NSCLC is infrequent, but associated with impaired survival following treatment with crizotinib.
    Thunnissen E; Lissenberg-Witte BI; van den Heuvel MM; Monkhorst K; Skov BG; Sørensen JB; Mellemgaard A; Dingemans AMC; Speel EJM; de Langen AJ; Hashemi SMS; Bahce I; van der Drift MA; Looijen-Salamon MG; Gosney J; Postmus PE; Samii SMS; Duplaquet F; Weynand B; Durando X; Penault-Llorca F; Finn S; Grady AO; Oz B; Akyurek N; Buettner R; Wolf J; Bubendorf L; Duin S; Marondel I; Heukamp LC; Timens W; Schuuring EMD; Pauwels P; Smit EF
    Lung Cancer; 2019 Dec; 138():13-18. PubMed ID: 31630043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Sensitive ALK Immunohistochemistry Companion Diagnostic Test Identifies Patients Eligible for Treatment with Crizotinib.
    Thorne-Nuzzo T; Williams C; Catallini A; Clements J; Singh S; Amberson J; Dickinson K; Gatalica Z; Ho SN; Loftin I; McElhinny A; Towne P
    J Thorac Oncol; 2017 May; 12(5):804-813. PubMed ID: 28147239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ALK fusion variants detection by targeted RNA-next generation sequencing and clinical responses to crizotinib in ALK-positive non-small cell lung cancer.
    McLeer-Florin A; Duruisseaux M; Pinsolle J; Dubourd S; Mondet J; Phillips Houlbracq M; Magnat N; Fauré J; Chatagnon A; de Fraipont F; Giaj Levra M; Toffart AC; Ferretti G; Hainaut P; Brambilla E; Moro-Sibilot D; Lantuejoul S
    Lung Cancer; 2018 Feb; 116():15-24. PubMed ID: 29413046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Case report: Clinical complete response in advanced ALK-positive lung squamous cell carcinoma: a case study of successful anti-PD-1 immunotherapy post ALK-TKIs failure.
    Yang C; Zeng R; Zha Y; Li Y; Wang T; Zhao R; Li M; Zhang J
    Front Immunol; 2024; 15():1360671. PubMed ID: 38380327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combining ALK Fluorescent In Situ Hybridization and Immunohistochemistry to Analyze Multiple Non-Small Cell Lung Carcinoma Samples per Patient Reveals Intermethod and Intersample-discrepant Results.
    Lambros L; Ginestet F; Quintin-Roué I; Le Flahec G; Uguen A
    Appl Immunohistochem Mol Morphol; 2019 Sep; 27(8):565-571. PubMed ID: 30499816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification and therapeutic evaluation of ALK rearrangements in non-small-cell lung cancer.
    Zhao R; Guo L; Zhang B; Zhao J; Xiang C; Chen S; Shao J; Zhu L; Ye M; Han Y
    J Pathol Clin Res; 2022 Nov; 8(6):538-549. PubMed ID: 35848751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic value of a novel fully automated immunochemistry assay for detection of ALK rearrangement in primary lung adenocarcinoma.
    Ying J; Guo L; Qiu T; Shan L; Ling Y; Liu X; Lu N
    Ann Oncol; 2013 Oct; 24(10):2589-2593. PubMed ID: 23904459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluorescence in situ hybridization, immunohistochemistry, and next-generation sequencing for detection of EML4-ALK rearrangement in lung cancer.
    Pekar-Zlotin M; Hirsch FR; Soussan-Gutman L; Ilouze M; Dvir A; Boyle T; Wynes M; Miller VA; Lipson D; Palmer GA; Ali SM; Dekel S; Brenner R; Bunn PA; Peled N
    Oncologist; 2015 Mar; 20(3):316-22. PubMed ID: 25721120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simultaneous VENTANA IHC and RT-PCR testing of ALK status in Chinese non-small cell lung cancer patients and response to crizotinib.
    Xu CW; Wang WX; Chen YP; Chen Y; Liu W; Zhong LH; Chen FF; Zhuang W; Song ZB; Chen XH; Huang YJ; Guan YF; Yi X; Lv TF; Zhu WF; Lu JP; Wang XJ; Shi Y; Lin XD; Chen G; Song Y
    J Transl Med; 2018 Apr; 16(1):93. PubMed ID: 29642919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Custom Gene Capture and Next-Generation Sequencing to Resolve Discordant ALK Status by FISH and IHC in Lung Adenocarcinoma.
    Jang JS; Wang X; Vedell PT; Wen J; Zhang J; Ellison DW; Evans JM; Johnson SH; Yang P; Sukov WR; Oliveira AM; Vasmatzis G; Sun Z; Jen J; Yi ES
    J Thorac Oncol; 2016 Nov; 11(11):1891-1900. PubMed ID: 27343444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discordant
    Tobiášová K; Barthová M; Janáková Ľ; Lešková K; Farkašová A; Loderer D; Grendár M; Plank L
    Int J Mol Sci; 2024 Jul; 25(15):. PubMed ID: 39125737
    [No Abstract]   [Full Text] [Related]  

  • 20. Detection of known and novel ALK fusion transcripts in lung cancer patients using next-generation sequencing approaches.
    Vendrell JA; Taviaux S; Béganton B; Godreuil S; Audran P; Grand D; Clermont E; Serre I; Szablewski V; Coopman P; Mazières J; Costes V; Pujol JL; Brousset P; Rouquette I; Solassol J
    Sci Rep; 2017 Oct; 7(1):12510. PubMed ID: 28970558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.